Hormone Therapy

The benefits of gender-affirming hormone therapy outweigh the risks for transgender women of all ages as well as those with comorbidities, according to a speaker at the 2022 North American Menopause Society annual meeting.

Healio and Cardiology Today have aggregated a list of the most-read news in cardiology of September 2022.

RANCHO PALOS VERDES, Calif. — Menopausal hormone therapy can help alleviate severe vasomotor symptoms, but cardiologists should assess CV risk and consider several other factors when evaluating these patients, according to a speaker.

Women born in 1954 and 1966 were nearly twice as likely to experience daily hot flashes at age 50 years than women born in 1918 and 1930, regardless of obesity, smoking status, stress and hormonal therapy, according to study data.

In a large cohort of men, pre‐diagnostic use of metformin and testosterone replacement therapy was associated with lower incidence of prostate and colorectal cancers, but not male breast cancer, according to research.

Findings of this review suggest that gender-affirming hormone therapy may increase serum creatinine among transgender men but has the opposite effect among transgender women.

A recent study showed that menopausal hormone therapy or vaginal estrogen therapy did not increase the risk for breast cancer recurrence among postmenopausal women with early-stage, ER-positive disease.

Menopausal hormone therapy or vaginal estrogen therapy did not appear associated with increased risk for breast cancer recurrence or mortality among postmenopausal women with early-stage, ER-positive disease, according to study results.

The North American Menopause Society released an updated position statement confirming that the benefits of menopausal hormone therapy outweigh the risks for most women.

Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause, according to an updated position statement from the North American Menopause Society.